MW181 pretreatment confirmed its optimum effect in reducing phosphorylation of p38 MAPK (T180/Y182) and tau (AT8 site) at 70 and 90min (Fig
MW181 pretreatment confirmed its optimum effect in reducing phosphorylation of p38 MAPK (T180/Y182) and tau (AT8 site) at 70 and 90min (Fig. 1f, h). gavage) significantly decreased p38 MAPK activation in comparison with vehicle-administered hTau mice. This kind of also triggered a significant decrease in AT180 (pT231) site tau phosphorylation and Sarkosyl-insoluble tau aggregates. Third,…